Organon & Co (OGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Organon & Co stock (OGN) is currently trading at $6.11. Organon & Co PE ratio is 8.38. Organon & Co PS ratio (Price-to-Sales) is 0.25. Analyst consensus price target for OGN is $9.00. WallStSmart rates OGN as Underperform.
- OGN PE ratio analysis and historical PE chart
- OGN PS ratio (Price-to-Sales) history and trend
- OGN intrinsic value — DCF, Graham Number, EPV models
- OGN stock price prediction 2025 2026 2027 2028 2029 2030
- OGN fair value vs current price
- OGN insider transactions and insider buying
- Is OGN undervalued or overvalued?
- Organon & Co financial analysis — revenue, earnings, cash flow
- OGN Piotroski F-Score and Altman Z-Score
- OGN analyst price target and Smart Rating
Organon & Co
📊 No data available
Try selecting a different time range
OGN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Organon & Co (OGN)
OGN trades 57% above its Graham fair value of $4.90, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Organon & Co (OGN) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/sales, institutional own.. Concerns around revenue growth and eps growth. Mixed signals suggest waiting for clearer direction before acting.
Organon & Co (OGN) Key Strengths (3)
Every $100 of shareholder equity generates $31 in profit
Paying less than $1 for every $1 of annual revenue
77.86% of shares held by major funds and institutions
Supporting Valuation Data
Organon & Co (OGN) Areas to Watch (6)
Revenue declining -5.30%, a shrinking business
Earnings declining -55.80%, profits shrinking
Very thin margins, barely profitable
Small-cap company with higher risk but more growth potential
Decent operational efficiency, solid but not exceptional
Fairly priced relative to book value
Organon & Co (OGN) Detailed Analysis Report
Overall Assessment
This company scores 49/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 3 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 3.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (0.25) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 30.60%.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, Profit Margin. Some valuation metrics including Price/Book (2.09) suggest expensive pricing. Growth concerns include Revenue Growth at -5.30%, EPS Growth at -55.80%, which may limit upside. Profitability pressure is visible in Operating Margin at 16.20%, Profit Margin at 3.01%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 30.60% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -5.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OGN's Price-to-Sales ratio of 0.25x trades at a deep discount to its historical average of 0.82x (0th percentile). The current valuation is 84% below its historical high of 1.6x set in May 2022, and 1% above its historical low of 0.25x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Organon & Co (OGN) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Organon & Co faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 6.2B with 5% decline year-over-year. Profit margins are strong at 301.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 3060.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 301.0% and operating margin of 16.2% demonstrate strong pricing power and operational efficiency.
Revenue contracted 5% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Dividend sustainability with a current yield of 5.4%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Organon & Co.
Bottom Line
Organon & Co faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Organon & Co(OGN)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.